Sarepta Therapeutics, Inc. (SRPT) SEC filings

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value

$16.07+0.06 (+0.37%)

Close on Nov 13, 2026Market cap $1.70BP/E –Yield –

SEC filings

40 of Sarepta Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 23, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 6, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 4, 2026	Apr 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 2, 2026	SEC EDGAR
Current report	8-K	Feb 25, 2026	Feb 25, 2026	SEC EDGAR
Current report	8-K	Feb 25, 2026	Feb 25, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 18, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Dec 10, 2025	Dec 11, 2025	SEC EDGAR
Current report	8-K	Dec 7, 2025	Dec 8, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Aug 28, 2025	Aug 29, 2025	SEC EDGAR
Current report	8-K	Aug 18, 2025	Aug 21, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 13, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Jul 21, 2025	Jul 21, 2025	SEC EDGAR
Current report	8-K	Jul 14, 2025	Jul 16, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 6, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 6, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 24, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 28, 2025	SEC EDGAR
Current report	8-K	Feb 26, 2025	Feb 26, 2025	SEC EDGAR
Current report	8-K	Feb 13, 2025	Feb 14, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Current report	8-K	Nov 24, 2024	Nov 26, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Sep 12, 2024	Sep 16, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 7, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 1, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 6, 2024	Apr 24, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Feb 28, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Sarepta Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Jul 12, 2012
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SRPT.

Compare: SRPT vs PTCT · SRPT vs BBIO · SRPT vs INSM · SRPT vs IONS · SRPT vs BMRN

Revenue growth-18.9% · median 11.2%

Gross margin111.1% · median 89.4%

Operating margin-2.5% · median -37.1%

Net margin-5.9% · median -24.5%

Company	Revenue	Growth
BMRN	$3.41B	+11.2%
SRPT	$1.96B	-18.9%
INSM	$1.52B	+240.0%
PTCT	$1.16B	-35.1%
IONS	$960.09M	-0.7%
BBIO	$945.54M	+167.3%

Company

Next earnings (est.): Feb 24, 2027, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 835
Held by institutions: 100.0%
Auditor: KPMG LLP
SEC CIK: 873303

Advertisement
300 × 250

See a number that looks wrong?